CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 87,500 target
Drug / intervention
Magnesium Sulfate +3 moredrug
Likely dose
Magnesium Sulfate 10 gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01911494
NCT01911494N/ACompleted

The CLIP (Community Level Interventions for Pre-eclampsia) Cluster Randomized Controlled Trial

University of British Columbia·interventional·Posted Jul 30, 2013·Updated Jun 27, 2019

In Brief

A clinical study evaluating Community Engagement, PIERS on the Move mHealth decision aid, and 2 other interventions for Pre-eclampsia and Hypertension, Pregnancy Induced. Completed, enrolled 87,500 participants across 4 sites in 4 countries.

Detailed Summary

This project is being undertaken to test the hypothesis that implementing a community based package of care for women with hypertensive disorders of pregnancy will result in overall improvement in maternal and neonatal outcomes. This is based on the premise that there are three main modifiable reasons why women (and their fetuses/newborns) die due to pregnancy complications: 1) delays by the woman herself in recognizing the seriousness of her condition; 2) delays in her being assessed and then transported to a center capable of providing effective and life-saving interventions; and 3) delays in the health facility in providing those interventions. The treatments for pre-eclampsia that are poorly accessed in LMIC are 1) magnesium sulfate (MgSO4) for prevention and treatment of the grand mal seizures of eclampsia; 2) oral antihypertensive medication to lower maternal BP to reduce the risk of stroke. The CLIP pilot and definitive cRCT will investigate whether the community level intervention including implementation of the CLIP package (oral antihypertensive therapy when indicated, intramuscular (i.m.) MgSO4 when indicated; and appropriate referral to an CEmOC facility when indicated) of care will reduce the incidence of all-cause maternal morbidity and mortality.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesIndia, Mozambique, Nigeria, Pakistan

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 30, 2013
Enrollment StartSep 1, 2013
Primary CompletionMay 1, 2018
Study CompletionJun 1, 2018
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 12.9 years ago

Interventions

Community Engagementbehavioral

The primary objective of the community engagement activities in CLIP will be to create awareness and action around the prevention of maternal morbidity and mortality due to pre-eclampsia/eclampsia. Community engagement involves the collective action of individuals, families, religious leaders, policy makers,

PIERS on the Move mHealth decision aiddevice

This mHealth application is to be used by community health workers in intervention clusters to guide collection of relevant clinical data during antenatal visits. This clinical data is used to generate a risk estimate for any women with hypertension based on the miniPIERS (Pre-eclampsia Integrated Estimate of Risk) clinical risk prediction model. This risk estimate in combination with other pre-defined treatment triggers (severe hypertension (\>160mmHg systolic) or proteinuria (\>3+ dipstick); absence of fetal movements for greater than 12 hours; signs of recent stroke of seizure) are collected in the app and based on this data recommendations for care of the woman are provided.

Magnesium Sulfatedrug

Women identified in intervention clusters by the community health worker during a study visit as being at high risk of- or having recently experienced- an eclamptic seizure will be given 10 g intramuscular magnesium sulfate prior to transfer to a nearby facility for further care.

Methyldopadrug

Women identified in intervention clusters as having severe hypertension (systolic greater than 160 mmHg) by the community health worker during a study visit will be given 750 mg of oral methyldopa prior to transfer to a nearby facility for further care.